Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 14

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 14
---
 prospectus               
 for a discussion of factors to consider carefully before deciding to invest in our Ordinary Shares.                                    |
| Nasdaq                        
 Capital Market trading symbol |     | We have applied to list                                                                                                                
 our Ordinary Shares on the Nasdaq Capital Market under the symbol “RGNT”. This offering is contingent upon the Ordinary                
 Shares being listed on the Nadaq Capital Market, and no assurance can be given that our application will be approved or that a trading 
 market will develop.                                                                                                                   |

The number of the Ordinary Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby are sold, and is based on 3,929,378 Ordinary Shares issued and outstanding as of the date of this prospectus. After giving prospective effect to the 2.5-for-1 Split, this number excludes:

| ● | 167,365 Ordinary Shares                                                                       
 issuable upon the exercise of warrants currently outstanding, at an exercise price of $15.20; |

| ● | 79,290 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to consultants under our incentive option plan outstanding as of such date, at an exercise 
 price of $3.97, of which 79,290 were vested as of such date;                                                                     |

| ● | 485,245 Ordinary Shares                                                                                                           
 issuable upon the exercise of options to be issued to the chairman of the board of directors upon the completion of this offering 
 under our incentive option plan, at an exercise price of NIS 0.004;                                                               |

| ● | 200,888 Ordinary Shares                                                                                                            
 issuable upon the exercise of options to be issued to consultants and certain investors upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.004;                                                                      |

| ● | Ordinary Shares underlying                                                                                                        
 warrants issuable to the Bridge Loan (as defined below) lenders to purchase such number of Ordinary Shares equal to two times the 
 respective loan amount of each Bridge Loan due to such lenders, based on a price per share equal to 75% of the lowest price per   
 Ordinary Share during the first five trading days following the consummation of this offering;                                    |

| ● | Ordinary Shares                                                                                                                      
 underlying warrants issuable to the 2024 Loan Agreements (as defined below) lenders to purchase such number of Ordinary Shares equal 
 to two times the respective loan amount of each 2024 Loan Agreement due to such lenders, based on a price